IP Library › Granted Patent US 12,016,865
Granted Patent B2
US 12,016,865 · App. 16/229,898 · Granted Jun 25, 2024

Methods and pharmaceutical compositions for treating candida auris in blood

Inventors: Robert DiLuccio (Haymarket, VA); Bruce Reidenberg (Rye, NY)
Assignee: Cormedix Inc.
A61K31/549A61K9/4833A61K9/4891A61K9/5161A61K47/555A61P31/10
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,016,865
App. No.
16/229,898
Granted
Jun 25, 2024
Kind
B2
Abstract

A method for treating Candida auris in blood, comprising administering to the blood taurolidine, and/or one or more taurolidine derivatives, in a concentration which is effective to treat C. auris in the blood.

Claims (20)

1. A method for treating Candida auris in blood of a patient, the method comprising:

providing taurolidine in powder form;

forming a suspension of the powder form of taurolidine wherein the concentration of taurolidine in the suspension is one from the group consisting of about 0.5%, 1.0%, 2.0% and 4.0% w/v; and

parenterally delivering the suspension to the blood of the patient to treat C. auris in the blood of the patient.

2. A method according to claim 1 wherein the suspension is buffered to the pH of blood.

3. A method according to claim 1 wherein the suspension further comprises substances that increase cellular permeability of the suspension.

4. A method according to claim 1 wherein the suspension further comprises anticoagulants.

5. A method according to claim 1 wherein the powder form of taurolidine is suspended in water.

6. A method according to claim 1 wherein the powder form of taurolidine is suspended in saline.

7. A method according to claim 1 wherein the suspension is delivered intravenously.

8. A method for treating Candida auris in blood of a patient, the method comprising:

providing taurolidine in powder form;

forming a solution of the powder form of taurolidine wherein the concentration of taurolidine in the solution is one from the group consisting of about 0.5%, 1.0%, 2.0% and 4.0% w/v; and

parenterally delivering the solution to the blood of the patient to treat C. auris in the blood of the patient.

9. A method according to claim 8 wherein the solution is buffered to the pH of blood.

10. A method according to claim 8 wherein the solution further comprises substances that increase cellular permeability of the solution.

11. A method according to claim 8 wherein the solution further comprises anticoagulants.

12. A method according to claim 8 wherein the powder form of taurolidine is suspended in water.

13. A method according to claim 8 wherein the powder form of taurolidine is suspended in saline.

14. A method according to claim 8 wherein the solution is delivered intravenously.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 15, 2020
From: REIDENBERG, BRUCE
To: CORMEDIX INC.
Reel/Frame 053216/0819 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 17, 2019
From: DILUCCIO, ROBERT
To: CORMEDIX INC.
Reel/Frame 049777/0914 →
Continuity (2)
Provisional Application 62608843 · Dec 21, 2017
Related Publication 20190192529A1 · Jun 27, 2019